Full pipelines and rising revenues lead rare disease biotechs to restyle themselves as more mature, global biopharma companies.Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies after strong performances in 2025.Several rare disease biotechs hailed commercial successes in 2025 as marking a turning point […]
